Growth hormone treatment in pediatric burns

A safe therapeutic approach

Roque J. Ramirez, Steven E. Wolf, Robert E. Barrow, David N. Herndon

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

Objective: To determine the safety and efficacy of recombinant human growth hormone (rhGH) in the treatment of children who are severely burned. Summary Background Data: During the last decade, we have used recombinant human growth hormone (rhGH; 0.2 mg/kg/day SQ) to successfully treat 130 children with more than 40% total body surface area (TBSA) burns to enhance wound healing and decrease protein loss. A significant increase in the mortality of adult patients in the intensive care unit who were given rhGH has recently been reported in two large European trials which questions the therapeutic safety of rhGH. Methods: The records of 263 children who were burned were reviewed. Patients receiving either rhGH at 0.2 mg/kg/day subcutaneously as part of a randomized clinical trial (n = 48) or therapeutically (n = 82) were compared with randomized placebo-administered controls (n = 54), contiguous matched controls (n = 48), and matched patients admitted after August 1997, after which no patients were treated with rhGH (n = 31). Morbidity and mortality, which might be altered by rhGH therapy, were considered with specific attention to organ function or failure, infection, hemodynamics, and calcium, phosphorous, and albumin balance. Results: A 2% mortality was observed in both rhGH and saline placebo groups in the controlled studies, with no differences in septic complications, organ dysfunction, or heart rate pressure product identified. In addition, no difference in mortality could be shown for those given rhGH therapeutically versus their controls. No patient deaths were attributed to rhGH in autopsies reviewed by observers blinded to treatment. Hyperglycemic episodes and exogenous insulin requirements were higher among rhGH recipients, whereas exogenous albumin requirements and the development of hypocalcemia was reduced. Conclusions: Data indicate that rhGH used in the treatment of children who were severely burned is safe and efficacious.

Original languageEnglish (US)
Pages (from-to)439-448
Number of pages10
JournalAnnals of Surgery
Volume228
Issue number4
DOIs
StatePublished - Oct 1998

Fingerprint

Human Growth Hormone
Burns
Growth Hormone
Pediatrics
Therapeutics
Mortality
Albumins
Placebos
Safety
Hypocalcemia
Body Surface Area
varespladib methyl
Wound Healing
Intensive Care Units
Autopsy
Randomized Controlled Trials
Heart Rate

ASJC Scopus subject areas

  • Surgery

Cite this

Growth hormone treatment in pediatric burns : A safe therapeutic approach. / Ramirez, Roque J.; Wolf, Steven E.; Barrow, Robert E.; Herndon, David N.

In: Annals of Surgery, Vol. 228, No. 4, 10.1998, p. 439-448.

Research output: Contribution to journalArticle

Ramirez, Roque J. ; Wolf, Steven E. ; Barrow, Robert E. ; Herndon, David N. / Growth hormone treatment in pediatric burns : A safe therapeutic approach. In: Annals of Surgery. 1998 ; Vol. 228, No. 4. pp. 439-448.
@article{6bfa65af03a54767b4e55717345718ad,
title = "Growth hormone treatment in pediatric burns: A safe therapeutic approach",
abstract = "Objective: To determine the safety and efficacy of recombinant human growth hormone (rhGH) in the treatment of children who are severely burned. Summary Background Data: During the last decade, we have used recombinant human growth hormone (rhGH; 0.2 mg/kg/day SQ) to successfully treat 130 children with more than 40{\%} total body surface area (TBSA) burns to enhance wound healing and decrease protein loss. A significant increase in the mortality of adult patients in the intensive care unit who were given rhGH has recently been reported in two large European trials which questions the therapeutic safety of rhGH. Methods: The records of 263 children who were burned were reviewed. Patients receiving either rhGH at 0.2 mg/kg/day subcutaneously as part of a randomized clinical trial (n = 48) or therapeutically (n = 82) were compared with randomized placebo-administered controls (n = 54), contiguous matched controls (n = 48), and matched patients admitted after August 1997, after which no patients were treated with rhGH (n = 31). Morbidity and mortality, which might be altered by rhGH therapy, were considered with specific attention to organ function or failure, infection, hemodynamics, and calcium, phosphorous, and albumin balance. Results: A 2{\%} mortality was observed in both rhGH and saline placebo groups in the controlled studies, with no differences in septic complications, organ dysfunction, or heart rate pressure product identified. In addition, no difference in mortality could be shown for those given rhGH therapeutically versus their controls. No patient deaths were attributed to rhGH in autopsies reviewed by observers blinded to treatment. Hyperglycemic episodes and exogenous insulin requirements were higher among rhGH recipients, whereas exogenous albumin requirements and the development of hypocalcemia was reduced. Conclusions: Data indicate that rhGH used in the treatment of children who were severely burned is safe and efficacious.",
author = "Ramirez, {Roque J.} and Wolf, {Steven E.} and Barrow, {Robert E.} and Herndon, {David N.}",
year = "1998",
month = "10",
doi = "10.1097/00000658-199810000-00001",
language = "English (US)",
volume = "228",
pages = "439--448",
journal = "Annals of Surgery",
issn = "0003-4932",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Growth hormone treatment in pediatric burns

T2 - A safe therapeutic approach

AU - Ramirez, Roque J.

AU - Wolf, Steven E.

AU - Barrow, Robert E.

AU - Herndon, David N.

PY - 1998/10

Y1 - 1998/10

N2 - Objective: To determine the safety and efficacy of recombinant human growth hormone (rhGH) in the treatment of children who are severely burned. Summary Background Data: During the last decade, we have used recombinant human growth hormone (rhGH; 0.2 mg/kg/day SQ) to successfully treat 130 children with more than 40% total body surface area (TBSA) burns to enhance wound healing and decrease protein loss. A significant increase in the mortality of adult patients in the intensive care unit who were given rhGH has recently been reported in two large European trials which questions the therapeutic safety of rhGH. Methods: The records of 263 children who were burned were reviewed. Patients receiving either rhGH at 0.2 mg/kg/day subcutaneously as part of a randomized clinical trial (n = 48) or therapeutically (n = 82) were compared with randomized placebo-administered controls (n = 54), contiguous matched controls (n = 48), and matched patients admitted after August 1997, after which no patients were treated with rhGH (n = 31). Morbidity and mortality, which might be altered by rhGH therapy, were considered with specific attention to organ function or failure, infection, hemodynamics, and calcium, phosphorous, and albumin balance. Results: A 2% mortality was observed in both rhGH and saline placebo groups in the controlled studies, with no differences in septic complications, organ dysfunction, or heart rate pressure product identified. In addition, no difference in mortality could be shown for those given rhGH therapeutically versus their controls. No patient deaths were attributed to rhGH in autopsies reviewed by observers blinded to treatment. Hyperglycemic episodes and exogenous insulin requirements were higher among rhGH recipients, whereas exogenous albumin requirements and the development of hypocalcemia was reduced. Conclusions: Data indicate that rhGH used in the treatment of children who were severely burned is safe and efficacious.

AB - Objective: To determine the safety and efficacy of recombinant human growth hormone (rhGH) in the treatment of children who are severely burned. Summary Background Data: During the last decade, we have used recombinant human growth hormone (rhGH; 0.2 mg/kg/day SQ) to successfully treat 130 children with more than 40% total body surface area (TBSA) burns to enhance wound healing and decrease protein loss. A significant increase in the mortality of adult patients in the intensive care unit who were given rhGH has recently been reported in two large European trials which questions the therapeutic safety of rhGH. Methods: The records of 263 children who were burned were reviewed. Patients receiving either rhGH at 0.2 mg/kg/day subcutaneously as part of a randomized clinical trial (n = 48) or therapeutically (n = 82) were compared with randomized placebo-administered controls (n = 54), contiguous matched controls (n = 48), and matched patients admitted after August 1997, after which no patients were treated with rhGH (n = 31). Morbidity and mortality, which might be altered by rhGH therapy, were considered with specific attention to organ function or failure, infection, hemodynamics, and calcium, phosphorous, and albumin balance. Results: A 2% mortality was observed in both rhGH and saline placebo groups in the controlled studies, with no differences in septic complications, organ dysfunction, or heart rate pressure product identified. In addition, no difference in mortality could be shown for those given rhGH therapeutically versus their controls. No patient deaths were attributed to rhGH in autopsies reviewed by observers blinded to treatment. Hyperglycemic episodes and exogenous insulin requirements were higher among rhGH recipients, whereas exogenous albumin requirements and the development of hypocalcemia was reduced. Conclusions: Data indicate that rhGH used in the treatment of children who were severely burned is safe and efficacious.

UR - http://www.scopus.com/inward/record.url?scp=0032471179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032471179&partnerID=8YFLogxK

U2 - 10.1097/00000658-199810000-00001

DO - 10.1097/00000658-199810000-00001

M3 - Article

VL - 228

SP - 439

EP - 448

JO - Annals of Surgery

JF - Annals of Surgery

SN - 0003-4932

IS - 4

ER -